share_log

Immunocore Secures Reimbursement Agreement In England For KIMMTRAK To Treat HLA-A*02:01-Positive Adults With Unresectable Or Metastatic Uveal Melanoma

Benzinga ·  Dec 3 15:07

Immunocore announces reimbursement agreement in England for KIMMTRAK▼ for the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma
"Today is a landmark day for the uveal melanoma community, with NICE's recommendation of the first treatment to prolong survival in HLA-A*02:01-positive adults with metastatic or unresectable uveal melanoma. Uveal melanoma is a very rare form of melanoma which requires different clinical management. The option to prescribe tebentafusp is a step change for patients and their families, and we continue to support the process so that there is reimbursement for the therapy across the UK for all eligible patients," said Susanna Daniels, CEO of Melanoma Focus.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment